Medacta 25th Anniversary World Tour continues with events in Australia and the United States focusing on Personalized and Sustainable Total Knee Arthroplasty 30.05.2024, 19:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Medacta Group 157,70 EUR -1,25 % Lang & Schwarz

Medacta Group SA / Key word(s): Miscellaneous/Miscellaneous
Medacta 25th Anniversary World Tour continues with events in Australia and the United States focusing on Personalized and Sustainable Total Knee Arthroplasty

30.05.2024 / 19:00 CET/CEST


MEDIA RELEASE

Medacta 25th Anniversary World Tour continues with events in Australia and the United States focusing on Personalized and Sustainable Total Knee Arthroplasty

CASTEL SAN PIETRO, May 30, 2024 – On the occasion of its 25th anniversary, Medacta Group SA ("Medacta," SIX:MOVE) announces the 4th Australian M.O.R.E. Knee Symposium in Sydney (AU) which will take place from May 30 to June 1, 2024, and the 2nd Kinematic Alignment Summit in Chicago (US) scheduled for June 7-8. These two events are part of a global scientific series, following the successful 10th M.O.R.E. International Symposium, held in Lugano, Switzerland, from April 15-19, 2024, focused on "the sustainability of personalized medicine and technology in orthopedics and spine surgery.".

"We are honored to welcome surgeons from all over the world and pleased to continue celebrating our 25th anniversary by hosting these upcoming scientific events focused on the knee, the segment that has changed the most for Medacta over the past five years, with our expanding and proven expertise in Kinematic Alignment” states Francesco Siccardi, CEO of Medacta “These events underscore our commitment and dedication to medical education, promoting the sharing of experience and knowledge among distinguished surgeons from around the world to improve care, outcomes, and patient well-being.

"It's important to leverage a comprehensive and versatile knee portfolio to help my patients during the different stages of knee pathologies," says Dr. Bu Balalla, Sydney, Australia. The 4th Australian M.O.R.E. Knee Symposium perfectly aligns with this approach, exploring the latest advancements in knee procedures, covering topics from sports medicine to revision, with the aim of improving both natural joint motion and biomechanics, ultimately leading to improved patient outcomes.  The complete Medacta knee portfolio supports surgeons with an innovative, personalized, and sustainable offering. It leverages the integration of MySolutions Personalized Ecosystem technologies, including the NextAR Knee Augmented Reality surgical application and MyKnee Patient-Matched solution, with the GMK Efficiency single-use instrument, holding the promise of improving accuracy, precision, and efficiency in knee surgeries.

Moreover, these scientific events will bring together renowned experts in the field to explore innovative approaches to knee arthroplasty, with a particular focus on Kinematic Alignment. "Kinematic Alignment has become one of the most-discussed concepts in TKA. Growing out of the desire to deliver a personalized approach to arthroplasty, KA has shown promising results in published literature with the potential to positively impact patient outcomes," states Dr. Keith Berend, New Albany, Ohio, USA. Kinematic Alignment, a surgical technique designed to restore the knee's function to its pre-arthritic state, has been shown to improve patient outcomes through numerous peer-reviewed studies. The event in the United States provides the perfect opportunity to discuss the initial results of the GMK SpheriKA implant, the first knee implant specifically designed for Kinematic Alignment procedures. Additionally, Medacta's MyKA platform offers surgeons a comprehensive solution to perform Kinematic Alignment safely and consistently. 

As Medacta celebrates its 25th anniversary this year, CEO Francesco Siccardi reflects on the company's ongoing commitment to medical education and innovation: "We are proud to celebrate our 25th anniversary by continuing to support our solutions and technologies through world-class medical education. Our dedication to advancing orthopedic care is unwavering, and we remain focused on what matters the most: improving patient outcomes worldwide."

Medacta 25th Anniversary World Tour concludes in Tokyo from October 12th to 14th.

For more information:

 

Contact
Gianluca Olgiati
Group Vice President Marketing
+41 91 696 60 60
media@medacta.ch

Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries. Follow us on Medacta TV, YouTube, LinkedIn and X.

 

RELATED TRADEMARKS

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. MySolutions™ Personalized Ecosystem, NextAR™, GMK®SpheriKA.

 


Additional features:

File: Medacta 25th Anniversary World Tour continues with events in Australia and the United States


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1913935

 
End of News EQS News Service

1913935  30.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1913935&application_name=news&site_id=boersennews_de~~~d41e2cc8-bdcb-47ba-bb51-c77a04513666
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer